How Nurses Manage Patients Receiving Peptide-Targeted Radiation Therapy for Neuroendocrine Tumors | Research

The takeaway

This practice review outlines the oncology nursing role in administering 177Lu-DOTATATE, a peptide-based radioligand therapy that targets somatostatin receptors on neuroendocrine tumors.

177Lu-DOTATATE
A radioactive peptide that binds somatostatin receptors on neuroendocrine tumor cells, delivering targeted radiation therapy — one of the most successful peptide-based cancer treatments

What the researchers found

This clinical practice review describes the nursing roles in administering peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTATATE for patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The peptide-based therapy targets somatostatin receptors expressed on neuroendocrine tumor cells, delivering targeted radiation directly to tumors. Oncology nurses play critical roles in patient assessment, education, direct care during infusion, monitoring for adverse effects, and providing emotional support throughout treatment.

Why it matters

PRRT with 177Lu-DOTATATE (Lutathera) represents one of the most successful applications of peptide-based targeted therapy in oncology. As this treatment becomes more widely adopted for neuroendocrine tumors, practical guidance on patient care is essential. This review provides the nursing perspective on managing patients receiving this peptide-targeted radioligand therapy, addressing a gap in clinical education.

How the study worked

Clinical practice review based on published literature and the authors' nursing experience. Includes a case study to illustrate key patient care concepts during PRRT administration.

Who was studied

Patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors receiving PRRT

What this study cannot tell us

This is a narrative practice review, not a research study. It does not present new clinical outcome data, efficacy results, or safety statistics. The guidance is based on the authors' institutional experience, which may not be universally applicable.

How to read the evidence

This is a clinical practice review based on published literature and nursing experience, not a primary research study. It provides practical guidance but no new clinical evidence. Evidence strength is low for treatment efficacy claims, though the underlying therapy (Lutathera) has strong clinical trial support.

When this study was published

Published in 2024, this review reflects current clinical practice for PRRT administration and is relevant to the growing adoption of peptide receptor radionuclide therapy.

The bigger picture

Peptide receptor radionuclide therapy is one of the landmark achievements in peptide-based medicine. 177Lu-DOTATATE (marketed as Lutathera) was approved by the FDA in 2018 after the NETTER-1 trial showed significant progression-free survival benefits. As PRRT adoption grows worldwide and expands to new tumor types, the practical infrastructure for safe administration — including specialized nursing care — becomes increasingly important. This review reflects the maturation of peptide-targeted radioligand therapy from clinical trial novelty to routine practice.

Questions still open

How will nursing protocols evolve as PRRT is combined with other therapies like checkpoint inhibitors or chemotherapy?
Could standardized nursing assessment tools specific to PRRT improve patient outcomes and side effect management?
As PRRT expands to new tumor types beyond GEP-NETs, what additional nursing competencies will be required?

Common questions

What is peptide receptor radionuclide therapy (PRRT)?

PRRT is a targeted cancer treatment that uses a radioactive peptide — a small protein fragment — to seek out and bind to specific receptors on tumor cells. In the case of 177Lu-DOTATATE, the peptide mimics somatostatin and binds to somatostatin receptors that are abundant on neuroendocrine tumor cells. Once bound, it delivers targeted radiation that destroys the cancer cells while largely sparing healthy tissue.

What kind of cancers does 177Lu-DOTATATE treat?

177Lu-DOTATATE (Lutathera) is approved for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors — cancers arising in the gut or pancreas that express high levels of somatostatin receptors. Research is ongoing to extend its use to other neuroendocrine tumors and potentially other cancer types.

Read the original research

Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE: Nursing Roles in Managing Patients With Gastroenteropancreatic Neuroendocrine Tumors.

Clinical journal of oncology nursing, 28(1), 79-87

View on PubMed ↗Publisher’s paper ↗

Citation

Bennett, Bonita; Gardner, Linda; Ryan, Pamela. (2024). Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE: Nursing Roles in Managing Patients With Gastroenteropancreatic Neuroendocrine Tumors.. Clinical journal of oncology nursing, 28(1), 79-87. https://doi.org/10.1188/24.CJON.79-87